FH535 suppresses the proliferation and motility of hepatocellular carcinoma cells

MINORU TOMIZAWA¹, FUMINOBU SHINOZAKI², YASUFUMI MOTOYOSHI³, TAKAO SUGIYAMA⁴, SHIGENORI YAMAMOTO⁵ and NAOKI ISHIGE⁶

Departments of ¹Gastroenterology, ²Radiology, ³Neurology, ⁴Rheumatology, ⁵Pediatrics and ⁶Neurosurgery, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan

Received August 28, 2015; Accepted October 9, 2015

DOI: 10.3892/ijo.2015.3220

Abstract. The Wnt signaling pathway is activated in hepatocellular carcinoma (HCC). This study investigated the effects of FH535, an inhibitor of the Wnt signaling pathway, on the proliferation and motility of HCC cells. HLF cells and PLC/PRF/5 cells, HCC cells, were subjected to 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay with the addition of FH535. RNA was isolated from the cells and subjected to real-time quantitative PCR. Hematoxylin and eosin (H&E) staining was performed to analyze apoptosis. A scratch assay was performed to analyze cell motility. Cell proliferation significantly decreased (P<0.05). The expression levels of cyclin D1 significantly decreased in both cell lines (P<0.05). Pyknotic nuclei were observed in the cells cultured with FH535 (50 µM). In the scratch assay, the distance between the growing edges of cells and the scratched line significantly decreased with the addition of FH535 at 50 µM (P<0.05). The expression levels of matrix metalloproteinase 9 significantly decreased at 50 µM (P<0.05). FH535 suppressed the proliferation of HCC cells by downregulating the expression of cyclin D1 and by inducing apoptosis. Further, it suppressed cell motility by downregulating the expression of matrix metalloproteinase.

Introduction

Hepatocellular carcinoma (HCC) is a cancer originating from the liver. Its prognosis is poor despite the advancements in treatment (1). Treatments for HCC include local ablation, surgery, transcatheter arterial chemoembolization, and chemotherapy (2,3). Molecular therapy has also been established as a treatment option (4). To develop a new molecular therapy, research has focused on signaling pathways (5).

Materials and methods

Cell culture. HLF cells and PLC/PRF/5 cells, human HCC cells, were obtained from RIKEN Cell Bank (Tsukuba, Japan) and cultured in Dulbecco's modified Eagle's medium (DMEM; Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS; Life Technologies, Grand Island, NY, USA). They were cultured in 10-cm dishes (Asahi Techno Glass, Funabashi, Japan) with 5% carbon dioxide at 37°C in a humidified chamber.

Cell proliferation assay. Cells were trypsinized, harvested, and spread onto 96-well plates (Asahi Techno Glass) at a density of 1,000 cells/well. They were cultured in DMEM...
supplemented with 10% FBS. The cells were cultured for 72 h with 0, 0.5, 1.5, 5, 15 or 50 µM FH535 (Merck, Darmstadt, Germany) and subjected to 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazoliun, inner salt (MTS) assay, according to the manufacturer's instructions (Promega Corp., Madison, WI, USA). MTS is reduced by cells to a colored formazan product that has an absorbance maximum at 490 nm. Absorbance was measured using an iMark Microplate Absorbance Reader (Bio-Rad, Hercules, CA, USA).

**Real-time quantitative polymerase chain reaction.** Total RNA (5 µg), which was isolated using Isogen (Nippon Gene, Tokyo, Japan), was used for the first-strand cDNA synthesis with SuperScript III and oligo(dT) following the manufacturer's instructions (Life Technologies). Real-time quantitative PCR was performed using Fast SYBR Green Master Mix (Life Technologies) with MiniOpticon (Bio-Rad). The results were analyzed using the MiniOpticon system. Real-time quantitative PCR was performed for 40 cycles, with 5 sec of denaturation and 5 sec of annealing/extension. The primer sequences are listed in Table I. RPL19 was used as an internal control as the target gene is a constitutively expressed housekeeping gene (16).

**Scratch assay and hematoxylin and eosin staining.** Cells were plated on 4-well chamber slides (Becton-Dickinson, Franklin Lakes, NJ, USA). When the cells reached confluence, they were scratched with a sterile razor. The cells were incubated with 0 or 50 µM FH535 for 48 h and stained with hematoxylin and eosin (H&E). For the analysis of apoptosis, the cells were plated in 4-well chamber slides (Becton-Dickinson). The cells were incubated with 0 or 50 µM FH535 for 48 h and then stained with H&E. The stained slides were observed under an AX80 microscope (Olympus, Tokyo, Japan) for the apoptosis analysis and scratch assay. In the scratch assay, the distance between the scratched line and the growing edges of the cells was measured at five points.

**Statistical analysis.** Data were analyzed by one-way analysis of variance (ANOVA) using JMP 10.0.2 software (SAS Institute, Cary, NC, USA). P-values <0.05 were considered statistically significant.

---

**Table I. The primer sequences.**

<table>
<thead>
<tr>
<th>Primer name</th>
<th>Sequence</th>
<th>Description</th>
<th>Product size (bp)</th>
<th>Annealing temperature</th>
<th>Cycle</th>
<th>GenBank</th>
</tr>
</thead>
<tbody>
<tr>
<td>OMC355</td>
<td>5'-AGAGGCCGAGGAGAAACACAG-3'</td>
<td>Cyclin D1, forward</td>
<td>180</td>
<td>60</td>
<td>40</td>
<td>NM_053056</td>
</tr>
<tr>
<td>OMC356</td>
<td>5'-AGGCCGTAGTAGGACAGAAGTTG-3'</td>
<td>Cyclin D1, reverse</td>
<td>89</td>
<td>60</td>
<td>40</td>
<td>NM_004994</td>
</tr>
<tr>
<td>OMC749</td>
<td>5'-CCTGGGCGATTCAAAAACT-3'</td>
<td>MMP9, forward</td>
<td>157</td>
<td>60</td>
<td>40</td>
<td>BC095445</td>
</tr>
<tr>
<td>OMC750</td>
<td>5'-GCAAGTCTTCCGAGTATTTGGAT-3'</td>
<td>MMP9, reverse</td>
<td>157</td>
<td>60</td>
<td>40</td>
<td>BC095445</td>
</tr>
</tbody>
</table>

MMP9, matrix metalloproteinase 9; RPL19, ribosomal protein L (RPL) 19.

---

**Figure 1. Cell proliferation assay.** Cell proliferation was analyzed with HLF cells (A) and PLC/PRF/5 cells (B) cultured in 96-well plates. The cells were incubated with FH535 (0, 0.5, 1.5, 5, 15, or 50 µM) and were subjected to MTS assay. Error bar, standard deviation; *P<0.05 as compared with 0 µM, n=3.

**Results**

To analyze the suppression of cell proliferation, HLF cells (Fig. 1A) and PLC/PRF/5 cells (Fig. 1B) were cultured with FH535. After 72 h, the cells were subjected to MTS assay. Proliferation was found to be significantly suppressed in both cell lines (P<0.05).
Cylin D1 is involved in the regulation of cell cycle progression (17). To evaluate the expression levels of cyclin D1, HLF cells (Fig. 2A) and PLC/PRF/5 cells (Fig. 2B) were incubated with FH535. After 48 h, RNA was isolated from the cells and subjected to real-time quantitative PCR. The expression levels of cyclin D1 were significantly suppressed in both cell lines (P<0.05).

To clarify the involvement of apoptosis in the suppression of cell proliferation, HLF (Fig. 3A and B) and PLC/PRF/5 cells (Fig. 3C and D) were incubated with FH535 at 0 µM (Fig. 3A and C) or 50 µM (Fig. 3B and D) and subjected to H&E staining. Pyknotic nuclei (arrows) were observed in the cells cultured with 50 µM FH535. These results indicate that the cells underwent apoptosis with FH535 at 50 µM.

To address the possibility that FH535 suppressed cell motility, HLF cells (Fig. 4A and C) and PLC/PRF/5 cells (Fig. 4B and D) were cultured with FH535 at 0 µM (Fig. 4A and C) or 50 µM (Fig. 4B and D). The distance between the growing edges of the cells and the scratched line significantly decreased with the addition of 50 µM FH535 (Fig. 4E) (P<0.05).

The expression levels of matrix metalloproteinase 9 were analyzed because this gene is involved in cancer metastasis (18). The expression levels of matrix metalloproteinase 9 were significantly suppressed in the HLF cells (Fig. 5A) and PLC/PRF/5 cells (Fig. 5B) (P<0.05).

**Discussion**

FH535 suppresses the proliferation of cancer cells. Specifically, in this study, it was observed to suppress the proliferation of HLF cells and PLC/PRF/5 cells. The expression levels of cyclin D1 decreased in both cell types after incubation with FH535. In the HCC cells, FH535 decreased the expression levels of cyclin D1 and suppressed the cell cycle (19).
results were consistent with those of the previous reports. The data clearly showed that the cells underwent apoptosis. The results indicated that FH535 suppressed cell proliferation by suppressing the cell cycle and inducing apoptosis.

FH535 suppresses cell motility as evidenced in the present study. In addition, FH535 is known to suppress the metastasis of HCC and pancreatic cancer cells (19,20). In this study, the expression levels of matrix metalloproteinase 9 decreased in HLF cells and PLC/PRF/5 cells. The previous reports and our data indicated that FH535 suppresses the motility of cancer cells by decreasing the expression levels of matrix metalloproteinase 9.

One possible limitation of this study is that the concentration of FH535 was relatively high. FH535 suppressed the proliferation and migration of HCC cells at 50 µM with statistical significance. In breast cancer cells, FH535 suppresses proliferation and migration at 1 µM (21). A higher concentration might be hazardous to cells, leading to adverse effects. To reduce this risk, using a combination of FH535 and other reagents would be desirable.

FH535 and sorafenib synergistically inhibit the proliferation of Huh-7 cells, another HCC cell line, and cancer stem cells (22). Another application of FH535 is in irradiation therapy (23). In the future, FH535 should be combined with other chemotherapeutic agents or small molecules.

In conclusion, FH535 suppressed cell proliferation by decreasing the expression of cyclin D1 and by inducing apoptosis. In addition, it suppressed cell motility by decreasing the expression of matrix metalloproteinase.

References